Southwest Research Institute

swri.org

Southwest Research Institute is an independent, nonprofit, applied research and development organization. The staff numbers nearly 2,600 professionals specializing in the creation and transfer of technology in engineering and the physical sciences. Total revenue for fiscal year 2017 was more than $528 million. SwRI headquarters occupy more than 1,200 acres in San Antonio, Texas, and provide more than 2 million square feet of laboratories, test facilities, workshops, and offices.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

news image

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More

Industrial Impact

MOMA THERAPEUTICS ANNOUNCES FIVE-YEAR DISCOVERY COLLABORATION WITH ROCHE FOCUSED ON CRITICAL CANCER DEPENDENCIES

MOMA Therapeutics | January 04, 2024

news image

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA’s Kn...

Read More

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

news image

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

Cell and Gene Therapy

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

news image

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More
news image

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More
news image

Industrial Impact

MOMA THERAPEUTICS ANNOUNCES FIVE-YEAR DISCOVERY COLLABORATION WITH ROCHE FOCUSED ON CRITICAL CANCER DEPENDENCIES

MOMA Therapeutics | January 04, 2024

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA’s Kn...

Read More
news image

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More
news image

Cell and Gene Therapy

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us